Melinta Therapeutics is an antibiotics-focused company that develops and commercializes antibiotics to overcome drug-resistant infections. Its four marketed products include Baxdela (delafloxacin), Vabomere (meropenem and vaborbactam), Orbactiv (oritavancin), and Minocin (minocycline) for injection. The Company also has an extensive pipeline of preclinical and clinical-stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market.
|Employees (est.) (Jun 2019)||261||(-1%)|
|Share Price (Oct 2019)||$4.4||(-4%)|
Market capitalization (17-Oct-2019)
Closing stock price (17-Oct-2019)
Melinta Therapeutics has 347 Twitter Followers. The number of followers has increased 0.7% month over month and increased 2.3% quarter over quarter
When was Melinta Therapeutics founded?
Melinta Therapeutics was founded in 2000.
Who are Melinta Therapeutics key executives?
Melinta Therapeutics's key executives are John Johnson, Sue Cammarata and Peter Milligan.
How many employees does Melinta Therapeutics have?
Melinta Therapeutics has 261 employees.
Who are Melinta Therapeutics competitors?
Competitors of Melinta Therapeutics include Cardiorentis, Genoa Pharmaceuticals and GBT (Global Blood Therapeutics).
Where are Melinta Therapeutics offices?
Melinta Therapeutics has an office in New Haven.
How many offices does Melinta Therapeutics have?
Melinta Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies